Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Next-generation sequencing (NGS) biomarker testing for metastatic non-small cell lung cancer (mNSCLC) offers cost savings and improved survival outcomes compared to polymerase chain reaction (PCR) testing over three years. NGS ensures faster access to appropriate targeted therapies, enhancing patient journeys.
Area Of Science
- Oncology
- Biomarker Discovery
- Health Economics
Background
- Metastatic non-small cell lung cancer (mNSCLC) management relies on accurate biomarker testing.
- Next-generation sequencing (NGS) offers comprehensive biomarker analysis compared to polymerase chain reaction (PCR).
- The economic and clinical impact of NGS versus PCR in mNSCLC from a payer perspective requires detailed assessment.
Purpose Of The Study
- To evaluate the comparative costs and clinical outcomes of NGS and PCR biomarker testing for newly diagnosed de novo mNSCLC patients.
- To analyze these outcomes from a US payer's viewpoint over a 3-year period.
Main Methods
- A Markov model simulated patient pathways following NGS or PCR testing.
- Model inputs included progression-free survival (PFS), overall survival (OS), and costs of testing, targeted therapy, and non-targeted therapy.
- Outcomes were assessed over 1, 2, and 3 years post-testing.
Main Results
- NGS testing was associated with per-patient cost savings of $7,386 at 1 year, $4,060 at 2 years, and $1,092 at 3 years compared to PCR.
- NGS patients experienced longer PFS and OS, with an additional 5.4 months PFS and 1.4 months OS in the first year.
- PCR testing led to higher costs due to inappropriate initiation of non-targeted therapy for missed actionable mutations.
Conclusions
- NGS biomarker testing in mNSCLC patients is projected to yield cost savings and improved PFS and OS compared to PCR testing.
- These benefits are evident as early as year 1 and persist over a 3-year timeframe.
- NGS facilitates more timely and appropriate targeted therapy, positively impacting patient outcomes and healthcare economics.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
